However, targeting S100A11 downregulation to attenuate liver tumor incidence, although potentially promising approach, it also leads to the downregulation of the hepatoprotective S100A10, which might explain the absence of beneficial outcome on tumor incidence. The gene discussed is S100A11; the disease is neoplasm.